SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF Trust is trending due to renewed global trade uncertainty, as President Trump's re-imposed 15% worldwide tariffs draw international pushback from the EU and India. The market community is deeply split between predictions of a significant market downturn and expectations for underlying resilience to absorb the news, with upcoming Nvidia earnings also in focus.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending significantly after reporting stellar Phase 2 clinical trial results for its sonelokimab drug in axial spondyloarthritis, showcasing strong efficacy and potential for disease modification. The community is buzzing with talks of a massive re-rating, potential buyout offers, and short squeeze opportunities, all intensified by a major institutional buyback and anticipation for its upcoming Investor Day.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver Corporation is trending due to its strong financial performance, marked by record revenue and treasury position, which has fueled community excitement and multi-year highs. Investors are particularly focused on the company's unique position as a pure-play silver miner with its own mint, allowing it to capture premiums amid a broader rally in precious metals and anticipated supply dynamics.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant downward pressure fueled by geopolitical tensions, substantial miner sell-offs, and large institutional liquidations, leading to a sharply divided community dialogue. Many foresee further declines and question its value proposition, while a segment views the current dip as a critical accumulation phase for a long-term store of value.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Community sentiment around XRP is sharply divided as anticipation builds for the potential passage of the U.S. Clarity for Digital Assets Act, which many believe would accelerate institutional adoption, bolstered by recent news of financial integrations. While some investors are accumulating, seeing a unique opportunity, others remain highly skeptical, pointing to historical volatility and perceived market manipulation as signals for continued price pressure.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is seeing heightened discussion as geopolitical tensions and ongoing market manipulation concerns drive significant bearish sentiment, while a contrarian faction eyes current price dips as a long-term accumulation opportunity.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending as its advanced counter-drone and defense technologies are highlighted for regional security needs in Mexico and through strategic investments in U.S. government contracts. The community is actively discussing the critical global demand for its solutions amidst evolving geopolitical tensions, driving strong bullish sentiment despite market volatility and talks of options manipulation.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following the FDA approval of its Bysanti drug for bipolar I disorder and schizophrenia, with many in the community anticipating a significant re-rating due to its new chemical entity status and patent protection extending to 2044, while some remain cautious about market dynamics and potential dilution.

Lizard

LIZARD CRYPTO is trending due to active community efforts to boost its viral status, driven by a meme contest and social media buzz, with many anticipating significant growth and potential major exchange listings for the meme coin, while others remain skeptical.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is trending amidst significant volatility, as technical support levels are tested following recent ETF outflows and profit-taking, fueling a divided community discussion between deeper corrections and long-term accumulation opportunities. Ongoing developments in institutional adoption, like the South Dakota House Bill 1155, continue to shape the narrative around its maturing role as a reserve asset.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brookline Cap M Weighs in on iBio's Q3 Earnings (NYSE:IBIO)

iBio, Inc. (NYSE:IBIO - Free Report) - Stock analysts at Brookline Cap M raised their Q3 2026 earnings estimates for shares of iBio in a report issued on Wednesday, February 11th. Brookline Cap M...

iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut shares of iBio from a "hold" rating to a "sell" rating in a research note on Saturday...

iBio Earnings Review: Q2 Summary

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

iBio (NASDAQ:IBIO) Stock Price Down 3.6% - Here's Why

iBio (NASDAQ:IBIO) Trading Down 3.6% - What's Next...

<ul class="summary-bullets"><li>iBio intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs.</li><li>This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.</li><li>The company also stated that it will use the funds to continue to progress other preclinical assets in the pipeline.</li></ul>Shares of iBio Inc. (IBIO) surged more than 12% in Friday’s pre-market trade after the company announced a private placement of securities worth $26 million.In its announcement, iBio stated that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for private placement financing. It expects the offering to close on or about Jan. 13, 2026, subject to customary closing conditions.iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.<h2 class="st-heading-2">Here’s What iBio Intends To Use Funds For</h2>In its announcement, iBio noted that it intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs. This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.Additionally, iBio said it will use the funds to advance other preclinical assets in the pipeline. The balance, if any, would be used toward meeting the company’s working capital requirements, iBio stated.The company added that the $26 million private placement extends its cash runway into 2028. It is also worth nearly 50% of iBio’s current market capitalization, which stood at nearly $53 million on Thursday.<h2 class="st-heading-2">What Does iBio Do?</h2>iBio is a San Diego, California-based company that is working on the development of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function.The company states that current GLP-1 treatments result in muscle loss in addition to fat loss. However, its therapeutic candidates for cardiometabolic diseases and obesity aim to preserve and build muscle mass during weight loss.iBio says it uses its patented artificial intelligence and machine learning platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘neutral’ territory at the time of writing.One user on the platform stated that the private placement is “bullish” news for the company, and that the “science here intrigues the industry.”<stembedurl>https://stocktwits.com/MiltonMilkyMilkovich/message/641313031</stembedurl><a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 22% year-to-date, but down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/what-is-fueling-smr-stock-surge-today/cmU2QIKR4dB">What Is Fueling SMR Stock's Surge Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement

iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.

Equity

Best Penny Stocks To Consider - December 10th

iBio, iBio, Momentus, Bitfarms, Richtech Robotics, Bit Digital, and Strive are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares...

Top Manufacturing Stocks To Keep An Eye On - December 10th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Flex, iBio, FREYR Battery, and Fabrinet are the seven Manufacturing stocks to watch today, according to...

Manufacturing Stocks To Research - December 8th

Taiwan Semiconductor Manufacturing, Applied Materials, Flex, Johnson Controls International, and iBio are the five Manufacturing stocks to watch today, according to MarketBeat's stock screener tool...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBIO News

IBIOiBio Inc